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Most SARS-CoV2 infections will not develop into severe COVID-19. However, in some
patients, lung infection leads to the activation of alveolar macrophages and lung epithelial
cells that will release proinflammatory cytokines. IL-6, TNF, and IL-1β increase expression
of cell adhesion molecules (CAMs) and VEGF, thereby increasing permeability of the
lung endothelium and reducing barrier protection, allowing viral dissemination and
infiltration of neutrophils and inflammatory monocytes. In the blood, these cytokines
will stimulate the bone marrow to produce and release immature granulocytes, that
return to the lung and further increase inflammation, leading to acute respiratory
distress syndrome (ARDS). This lung-systemic loop leads to cytokine storm syndrome
(CSS). Concurrently, the acute phase response increases the production of platelets,
fibrinogen and other pro-thrombotic factors. Systemic decrease in ACE2 function
impacts the Renin-Angiotensin-Kallikrein-Kinin systems (RAS-KKS) increasing clotting.
The combination of acute lung injury with RAS-KKS unbalance is herein called COVID-19
Associated Lung Injury (CALI). This conservative two-hit model of systemic inflammation
due to the lung injury allows new intervention windows and is more consistent with the
current knowledge.
Keywords: SARS-CoV2, COVID-19, severe COVID-19, bisphosphonates, inflammatory monocytes, ARDS,
renin-angiotensin system, kallikrein-kinin system
INTRODUCTION
Coronaviruses are a large family of enveloped viruses (Coronaviridae) containing a positive-sense
single-stranded RNA genome with a nucleocapsid. These viruses cause illness in both mammals
and birds. Within humans they cause respiratory tract infections that range from asymptomatic
infection to severe disease and death. Some coronaviruses have exhibited increased capacity to
infect and spread among humans, with higher lethality, causing diseases such as SARS, MERS,
and more recently, COVID-19. The causative virus of COVID-19 is the recently identified, severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). Depending on a number of currently
unknown factors, SARS-CoV-2 infection causes either asymptomatic infections or clinical disease,
which ranges from mild to life-threatening disease.
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Angiotensin Converting Enzyme 2 (ACE2) serves as the
main cell surface receptor, allowing the SARS-CoV-2 virus
to invade host cells (2). Transcriptome analysis of infected
epithelial cell lines and swab specimens from patients positive
for SARS-CoV-2 (qRT-PCR) showed mild increased reads of
ACE2, suggesting that ACE2 is an interferon-stimulated gene
(3–5). On the other hand, SARS-CoV have been reported to
reduce cell surface expression of ACE2 in vitro and in vivo
(6, 7). It is currently unknown how SARS-CoV-2 modulates
ACE2 transcription in the lung. SARS-CoV, and potentially
SARS-CoV-2, might impact extracellular ACE2 from normal
function via direct blocking during attachment and invasion,
intracellular modulation of the Unfolded Protein Response, and
decreased stability of ACE2 transcripts or altered translation
resulting in reduced protein levels. ACE2 functions biologically
to convert Angiotensin II (vasoconstrictor) into Angiotensin
(vasodilator), thus lowering blood pressure. Another function of
ACE2 is to decrease levels of Bradykinin, thus affecting the renin-
angiotensin system (RAS) and kallikrein-kinin system (KKS)
(8, 9). The balance between ACE/ACE2 affects vascular diseases
and higher Bradykinin can increase systemic inflammatory
processes (10). A review by Tolouian et al. discusses the possible
involvement of the RAS-KKS axis in COVID-19 (10). As RAS
has prothrombotic effects (11), part of the coagulation syndrome
seen in COVID-19 might be due to viruses escaping into the
blood stream and affecting ACE2 expression in the entire body.
Given the direct participation of ACE2 in both RAS and KKS,
it is likely that those systems directly contribute to local and
systemic inflammation.
Unlike viral load associated with SARS, MERS, and Influenza
(12) current data suggest there is no difference in upper
respiratory viral load between moderate and severe cases of
COVID-19 in hospitalized patients, with the exception of one
study in China (13–15). Most COVID-19 patients have upper
respiratory tract viral replication with mild symptoms, including
fever and dry cough, and recover without developing further
symptoms. It is possible that if SARS-CoV-2 reaches the lower
respiratory tract, the higher amount of ACE2 in alveoli results in
progression of infection into a more severe disease. Accordingly,
a recent study associates a higher viral load in the sputum
with severity of COVID-19 (16). About 20% of COVID-19
cases have fever coupled with pneumonia that progresses to
true ARDS, whereas some patients develop cytokine storm
associated ARDS that may be accompanied by features of the
Macrophage Activation Syndrome (MAS)/lymphohistiocytosis
(HLH) spectrum (17–19). The family of conditions due to
COVID-19 associated cytokine release was recently named
Cytokine Storm Syndrome (CSS) by Henderson et al. (20).
Cytokine storm (CS) is known to contribute to the morbidity
in patients infected with other coronaviruses (21, 22). There is
also a correlation between IL-6, C-reactive protein (CRP) and
respiratory failure in COVID-19 (23, 24). Yet, there is reason
to think CS is not the only source of morbidity, and we will
present evidence supporting this hypothesis. In addition to CS,
mounting evidence suggests an acute lung injury loop including
RAS-KKS unbalance, release of immature leukocytes from the
bone marrow, lung cellular infiltrate, vascular dysfunction,
and coagulopathy can contribute to morbidity and mortality
in COVID-19.
SYSTEMIC INFLAMMATORY RESPONSE
INDUCED BY LUNG INFLAMMATION
Recently, Wadman et al. provided a detailed perspective
regarding the diverse biological systems that display some level
of pathology during COVID-19 (25). Besides the lung, pathology
has been observed in the liver, kidneys, intestines, brain, heart,
and blood vessels. Despite the complexity of this multisystem
syndrome, the peer reviewed book chapter “Systemic
Inflammatory Response Induced by Lung Inflammation”
by Hiraiwa and van Eeden can shed important light guiding us
from the lung to the vascular syndrome without contradicting
the evidence seen in COVID-19 patients (26).
ARDS caused by SARS-CoV-2 is characterized by a rapidly
induced inflammatory response in the lung. The classification of
COVID-19 lung damage as ARDS is under scrutiny because the
severe hypoxemia is accompanied be a relatively mild decrease
in lung compliance (measurement of lung elastic properties),
suggesting that other mechanisms than direct parenchymal
injury may contribute to the degree of hypoxia. Some advocate
that the COVID-19 lung disease is covered by ARDS definition
(27), while others divide the lung damage into two phenotypes,
ARDS and not-ARDS (28, 29). Classification of COVID-19 lung
damage as ARDS and not-ARDS is not trivial and a deeper
comprehension of underlying mechanisms of COVID-19 lung
damage is critical to define the proper respiratory management
of these patients. For example, while there are evidence-based
treatment strategies for rigorously defined ARDS (including low
tidal volume ventilation, prone positioning, conservative fluid
management, and neuromuscular blockade), other mechanisms
of hypoxia such as pulmonary thrombi, acute pulmonary
vascular disease, or cardiac injury would necessitate completely
different treatment strategies. Previous data has shown that
both inadequate timing and strategy of artificial ventilation are
harmful to patients (30, 31). Consistent with these observations,
a case series from New York City (New York, USA) COVID-
19 patients, a high mortality rate (88%) was observed in the
artificially ventilated patients (32).
We propose a view of COVID-19 that is consistent
with prior understandings of lung physiology, where local
infections progress into systemic pathology associated with
exaggerated cytokine production, thrombosis, and multi-organ
damage/failure that heighten risk of death (19, 26). Clinical
events following severe tissue injury also activate the systemic
response of the host in a similar manner to sepsis and the
recognition of this common pathophysiologic phenotype led to
the term “systemic inflammatory response syndrome” or SIRS
(26). To address an overview of how a similar process might
be at play with COVID-19 we will divide the progression of
SARS-CoV-2 infection into four phases: (1) Upper and lower
respiratory tract infection, (2) COVID-19 associated lung injury
(CALI; Box 1), (3) SIRS, and (4) systemic failure (Figure 1).
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BOX 1 | COVID-19 Associated Lung Injury (CALI).
SARS-CoV-2 appears to induce acute lung injury similarly to other
respiratory viruses, but with additional symptoms derived from alterations in
the inflammatory resolution phase and RAS-KKS system, possibly due to
ACE2 downregulation, and/or elimination of pneumocytes type II (33). The
elimination of pneumocytes type II might explain the slow tissue recovery in
patients with severe COVID-19.
Upper and Lower Respiratory Tract
Infection
This phase would be the result of the infection itself. Virus
infection triggers antiviral innate immunity, resulting in Flu-like
symptoms, such as fever, fatigue, body ache, and others. There are
many drugs and treatments trying to stop virus multiplication in
this and other phases of the disease, some of them are elegantly
summarized by Kupferschmidt and Cohen (34). At this point,
most infected individuals will recover, and we would expect
them to be outpatients. Theoretically, patients would benefit from
antivirals as long as virions are present, but we hypothesize the
earlier the best to prevent CALI and its progression.
COVID-19 Associated Lung Injury (CALI)
When the virus reaches the lung, most patients will mount
a proper antiviral immune response (outpatients), with higher
lymphocyte presence in the lung contributing to viral elimination
(35–37). However, in some patients there will be exacerbated
local inflammation due to the activation of nucleic acid
sensors on lung epithelium and alveolar macrophages (38).
This will trigger autocrine and paracrine cytokine release and
other proinflammatory mediators, resulting in the recruitment
of polymorphonuclear neutrophils, monocytes, and other
leukocytes, which have been reported in lungs of patients
with COVID-19 (35, 36, 39, 40). Alveolar macrophages and
inflammatory monocytes are thought to be a source of IL-
6, TGF-β, TNF, IL-8, and IL-1β (38), whereas neutrophils
rapidly produce oxygen radicals, lipid mediators, and proteases
that can be harmful to viruses, but also to lung tissue (41).
Accordingly, single-cell RNA sequencing on bronchoalveolar
lavage fluid immune cells from COVID-19 patients has shown
the enrichment of macrophages and neutrophils with a strong
pro-inflammatory signature on monocyte-derived macrophages,
and the severity was associated with much higher levels of
IL8, IL6, TNF, and IL1B (39). Neutrophil extracellular traps
(NETs) have been associated with disease severity in COVID-
19 (42, 43). A review by Merad and Martin address many
details for the role of macrophages and monocytes in the
pathology of COVID-19 (44). Following exposure to air pollution
particles, alveolar macrophages and epithelial cells increase the
production of pro-inflammatory cytokines capable of stimulating
the bone marrow, resulting in higher numbers of band cells
(i.e., immature granulocytes) in circulation (45). In response to
acute inflammation, the liver releases C-reactive protein (CRP)
and Serum Amyloid A (SAA) that will increase in the first days
whether the patient develops moderate or severe symptoms.
Those levels might decrease after 7 days, depending on the
resolution of the injury, whereas haptoglobin and fibrinogen
(later seen as D-dimer) go up, possibly resulting in blood clots
(46). Pro-thrombotic factors are increased in COVID-19 patients
since early in the disease and its increase correlates with severe
respiratory syndrome (47–49).
Of note, arrested translation due to antiviral immunity
and viral manipulation of translational repression would
strongly impact protein expression by lung cells (50). ACE2
downregulation impacts the RAS-KKS system resulting
in coagulation disturbances, and increases the chances of
thrombosis and microthrombosis (10, 11). In malaria, the
acute respiratory distress syndrome also presents competitive
binding of other surface proteins, such as Endothelial Protein C
Receptor (EPCR), that when cleaves its ligand PAR-1, inhibits
NFκB activation, reducing overall local inflammation (51).
It is currently not known if SARS-CoV-2 infection results in
downregulation of those same surface proteins, resulting in
higher inflammatory response.
Another aspect of CALI that may occur is the upregulation
of endothelial cell adhesion molecules (CAMs) VCAM, ICAM,
VWF, ANG-2, and VEGF upon tissue injury. These proteins
are upregulated by pro-inflammatory cytokines, proteases,
leukotrienes, PAF, and oxidants produced by the neutrophils
(26). These factors may culminate in the destruction of the
lung glycocalyx, which may increase the permeability of the
endothelium, allowing the viruses to pass to the blood stream and
reach other organs that express ACE2. Thismay explain detection
of viral particles and RNA in other body fluids (52). Increased
permeability of microvascular barriers also results in protein-
rich edema fluid in airspaces, resulting in poor gas exchange and
decreased blood O2 levels, which are a central pathophysiological
mechanism in ARDS leading to hospitalizations. Autopsies
performed in different centers showed similar findings in
lungs from COVID-19 victims: diffuse alveolar disease (DAD)
combined with atypical pneumocytes and diffuse thrombosis of
small vessels (53–55).
For a proposed clinical-therapeutic staging, please refer to
Siddiqi and Mehra (19). Inpatients will most likely present
moderate to severe symptoms, possibly hypoxia (defined as
PaO2/FiO2 <300mmHg), thrombocytopenia, lymphocytopenia,
bilateral pneumonia, ground glass opacity (GGO), with mild
elevation of systemic inflammation. Different methods for
SARS-CoV2 detection allow inclusion of early biomarkers to
assess the quality of the cellular infiltrate and the lung state.
Here, we note the potential benefit of the combination of
antivirals, vasodilators (e.g., NO), and bisphosphonates for
inpatients with risk group comorbidities (Box 2) upon evaluation
of potential adverse risks. The idea is to prevent the lung-
systemic inflammatory loop in a similar way as fingolimod,
a sphingosine 1 phosphate analog that can affect lymphocyte
retention in lymphoid organs with a positive outcome reported
for COVID-19 (65). The family of bisphosphonates is used
in the treatment of osteoporosis, certain bone tumors, and
bone metastasis. Bisphosphonates are capable of reducing the
number and impairing function of monocytes and specialized
macrophages (66). Treatment with a member of this family,
clodronate disodium, has shown effectiveness in animal models
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FIGURE 1 | The four phases of SARS-CoV2 infection. (1) Upper and lower respiratory tract infection (outpatients); (2) COVID-19 associated lung injury (CALI), in which
some patients will be hospitalized (inpatients); (3) Systemic inflammatory response syndrome (SIRS), in which bone marrow and liver acute phase response
accumulate pro-thrombotic factors resulting in blood clots/thrombosis; (4) The sustained loop between lung and systemic inflammation results in multi-organ vascular
dysfunction and cytokine storm syndrome.
of pulmonary coronavirus infections (67), but the impact of
clodronate disodium on the microglia can also make animals
more susceptible to neural damage in a coronavirus encephalitis
model (68). Treatment of lung tissues with bisphosphonates
during COVID-19 could prevent inflammatory monocytes from
exaggerating lung injury. To date, there are no registered clinical
trials with bisphosphonates to treat COVID-19. One approach
to assess the potential effectiveness of this treatment would be to
access COVID-19 databases to address whether osteoporosis or
cancer patients under bisphosphonate treatments present better
COVID-19 prognostic compared to non-bisphosphonate treated
patients. Another study addressing monocytes/macrophages
used Diminazene Aceturate (DIZE), which is FDA approved for
animal use. DIZE treatment can ameliorate liver fibrosis in mice
through reducing ROS generation and pro-fibrotic cytokines
by Kupffer cells (69), which are liver-resident macrophages.
Additionally, DIZE treatment has also been shown to alleviate
lung injury in mice by regulating the ACE2-Ang (1, 7)-Mas axis
(70). Reduction of alveolar macrophages with bisphosphonates,
DIZE, or other approaches might have negative effects in
the resolution of ARDS. Yet, we were not able to find
significant drawbacks on respiratory disorders on patients under
bisphosphonate treatments within the 70 Clinical Trials that
have used bisphosphonate treatment (71). Moreover, studies
addressing lung cancer present potential beneficial effects (72).
Agonists of ACE2 or inhibitors of ACE/Ang2, are being
explored as treatments for COVID-19 patients (10), as they
would function to maintain the balance of the RAS-KKS system
and reduce further inflammation (70). Of note, Khan et al.
BOX 2 | Risk groups.
The models of systemic inflammatory response induced by lung injury
strongly suggest that lung inflammation is a “two-hit” model. Meaning that
underlying inflammation, either caused in the lung, or coming from another
site (e.g., cardiovascular diseases, obesity, diabetes, and liver disease) may
feedback into the lung upon a new infection like SARS-CoV2, resulting in the
exacerbation of the local and systemic inflammation. The RAS-KKS system
is also already affected in all those risk groups conditions, including aging
(56–64).
conducted a phase II trial in 10 critical care patients with
ARDS utilizing a recombinant ACE2 agonist to reduce lung
injury. Despite the expected effect in the RAS system, decreasing
the angiotensin II level, the study was stopped early because
oxygenation and lung compliance did not differ between groups
(73). Additionally, there was an unexpected increase in surfactant
protein D (SP-D) serum levels, which when present in the
blood marks increased capillary leakage (73). Collectively, these
observations suggest that ACE2 agonist or ACE inhibitors should
be pursued with caution.
Systemic Inflammatory Response
Syndrome
As described above, the loss of epithelial protection from the
glycocalyx and the increase in permeability factors (e.g., VEGF)
in the lung endothelial typical of SARS, might lead to the release
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of the virus and other PAMPS from the lungs to the blood stream
(26). Consistently, there are reports of SARS-CoV-2 mRNA
present in stool, blood and urine in severe COVID-19 patients
(52). In contrast, a study in nine SARS-CoV-2 infected patients
from the onset of infection until after the resolution of flu-like
symptoms, showed no viral RNA was found in the blood or
urine (74).
The systemic release of TNF-α, IL-1β, and IL-6 can impact
many organ systems, consistent with the multi-organ effect
observed in COVID-19 (18, 75). As mentioned above, alveolar
macrophages and airway epithelial cells are expected to be
the major source of those cytokines during COVID-19. Those
cytokines can hyperactivate monocytes/macrophages and T
lymphocytes and result in CSS andMAS/sHLH (20). More details
of the CSS consequences can be found in a perspective article
by Moore and June (18). In one study reporting on 54 COVID-
19 patients, 28 of those patients had severe respiratory failure
and all of them displayed either MAS or low HLA-DR, with
lymphocytopenia (17). Interestingly, up to 50% of patients with
systemic juvenile idiopathic arthritis and MAS/HLH present
nervous system involvement, ranging from mild confusion to
coma (76). Moreover, evidence of neuropathology has been
reported during COVID-19, including 26 out of 40 patients
noted to have confusion according to the Confusion Assessment
Method for the ICU (77). Given the apparent contribution
of MAS to progressing severity of COVID-19, treatment with
bisphosphonates provide a potential added benefit, although
we could not find studies addressing the potential effect of
bisphosphonates on MAS.
Bone marrow stimulation by acute lung injury derived
pro-inflammatory cytokines leads to the release of immature
granulocytes in the blood circulation (45). As adhesins are
upregulated in the lung endothelium, leukocyte infiltrate will be
present. Of note, leukocytes and immature leukocytes have been
reported in other lung injury scenarios to sequester in the lung
microvasculature where they contribute to tissue pathology and
inflammation (26). Sequestration of blood leukocytes may result
in low white blood cell count, which has been reported in severe
COVID-19 patients (49, 55, 78). CD8T cells are classical antiviral
responders, thus treatments targeting activation of lymphocytes
are likely to be protective early in the infection. An updated
meta-analysis by Soraya and Ulhaq define crucial laboratory
parameters that can be used in COVID-19 diagnosis and
prognosis, indicating that higher leukocyte counts, neutrophils,
D-dimer, and CRP positively correlates with severe COVID-
19 when compared to non-severe cases (79). As CD8 and
CD4T cells from COVID-19 patients do not express high levels
of exhaustion markers when in circulation, the investigation
of adequate windows of treatments targeting those cells is
essential (80).
Another important aspect of the bone marrow stimulation
is the increase in blood coagulability, which is a major
problem for patients with comorbidities. Lung derived IL-
6 stimulates hepatocytes to produce acute phase proteins,
such as CRP, fibrinogen and antiproteases, stimulating
hematopoiesis, specifically the production of platelets (26).
Platelets, leukocytes and erythrocytes can shed microparticles
(MP) associated with lung injury, and have been reported
in collagen vascular disorders. MP are known to be
involved in inflammation, coagulation, and are increased in
atherothrombotic cardiovascular diseases (81). Reports of
periphery and organ clotting are increasing in COVID-19
clinical description. It is noteworthy that systemic increased
endothelial adherence and permeability, reduced NO, higher
number of platelets and monocytes, higher production of ROS
and lipid content, higher proteinase activity, and lower fibrosis
cap of plaques might result in increased heart attacks and strokes
in those patients (25). Recently, there was a report of large-vessel
stroke in five patients younger than 50 years of age in NY (82).
Consequently, anticoagulants and regulators of RAS-KKS might
work at preventing clots and further vascular problems. Of
note, they have been used in coagulopathy with some degree
of success for COVID-19 (48). Many reports of coagulation
complications due to COVID-19 are happening after discharge
of patients. It seems that cytokine storm presentation is not
needed for the release of pro-thrombotic factors (repair attempt)
after CALI stimulation of the hepatocytes and bone marrow,
and the opposite is also true. As D-dimers are a subproduct of
inflammation triggered during sustained acute phase response, it
is of essence to target upstream cascades of inflammation using
antivirals, bisphosphonates, and anti-inflammatory treatments
in a timely manner.
Systemic Failure
When vascular permeability and systemic inflammation are
too high, vascular dysfunction, and inflammation might lead
to multiple organ failure (MOF), including respiratory failure
(25). Compassionate treatments are trying to address many
inflammatory aspects of the disease presentation (18). For
example, the anti-IL-6 antibody, Tocilizumab (TCZ) has been
used to dampen the inflammatory response. Reduction of IL-
6 might impact thrombus resolution, as reported in mice (83).
Differently, TCZ has shown some success at reducing Cytokine
Release Syndrome (CRS) during CD19 CART-cell therapy (84).
Accordingly, different studies using TCZ presented increased
likelihood of survival in patients with severe COVID-19 (85–
88). Another group reported that the earlier the treatment of
COVID-19 with TCZ, the better the likelihood of survival (89).
Anakinra, a recombinant IL-1 receptor antagonist, reduced both
need forMV in the ICU andmortality among patients with severe
COVID-19, in different cohort studies (90–94). Controlled trials
are still required.
As suggested by our proposed model, prevention of
the second-hit, or preventing the amplification of lung-
systemic inflammation loop, seems to be the best window for
intervention specially in patients with comorbidities. Although
immunomodulatory treatments will dampen aspects of the
pro-inflammatory response, the epithelial antiviral type I IFN
response will still be in effect, providing the immune system with
a mechanism to clear the SARS-CoV-2 infection. Importantly,
immunomodulatory drugs should be helped by the use of
antivirals whenever viral particles are still detected.
Coagulopathy appears to be critical in the context of COVID-
19. One study reported procoagulant presences even in early
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stages of COVID-19 (47), consistent with RAS-KKS unbalance
influencing the production of pro-thrombotic factors (11). The
collective coagulation problems accumulated in the other phases
of COVID-19 likely result in the observed high levels of fibrin
degradation product, D-dimer, longer prothrombin time, and
activated partial thromboplastin time in critically ill patients
compared to survivors (95). As noted above, systemic acute phase
response by the liver and bone marrow produce the bulk of pro-
thrombotic factors. It is noteworthy that microthrombosis are
compatible with increased severity of hypoxemia maintaining
lung compliance. Finally, other exacerbated immune response
factors are likely contributing to the coagulopathy, such as
inflammasome activation, NETs, endothelial cell infections
and pyroptosis.
We advocate an individualized approach to mechanical
ventilation (MV) parameters based on patient’s lung
mechanics as a support therapy. The current mortality
rate of patients under MV is alarmingly high (32, 96).
Many patients in need of MV arrive at the ICU with
systemic hyperinflammation, likely resulting in quicker
deterioration. Moreover, inadequate ventilation settings
might exacerbate lung injury and further contribute to lung-
systemic inflammation. Thus, individualized care and drug
therapies to prevent this feed-forward loop between lung-
systemic inflammation leading to MOF and coagulopathy are
urgently needed.
SUMMARY OF WHAT MIGHT BE
HAPPENING AFTER CALI IN SEVERE
COVID-19
Most SARS-CoV2 infections will not develop into severe
COVID-19. Upon lung injury (first hit), the host response will
determine the severity of the disease (35–37). In some patients,
lung infection leads to the activation of alveolar macrophages
and lung epithelial cells that will release proinflammatory
cytokines. IL-6, TNF, and IL-1β increase expression of cell
adhesion molecules (CAMs) and VEGF in the lung, thereby
increasing permeability of the lung endothelium and reducing
barrier protection, allowing viral dissemination and infiltration
of neutrophils and inflammatory monocytes. In the blood, these
cytokines will stimulate the bone marrow to produce and release
immature granulocytes, that return to the more adherent lung
endothelium and further increase lung inflammation, leading
to ARDS. This second hit in the lung leads to a loop of
systemic inflammation resulting in cytokine storm syndrome.
Concurrently, the acute phase response caused by the stimulation
of hepatocytes and bone marrow increases the production
of platelets, fibrinogen and other pro-thrombotic factors. The
systemic decrease in ACE2 function due to virus infection,
impacts RAS-KKS that culminate in increased clotting and
inflammation. The disbalance of the RAS-KKS is common
in patients with comorbidities, and affects the lung, kidneys,
FIGURE 2 | Two-hit model of systemic inflammation derived from COVID-19 associated lung injury.
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liver, brain and the gastrointestinal system (97). All of which
culminates in respiratory failure, coagulopathy and potential
multiple organ failure (MOF) (Figure 2).
FURTHER CONSIDERATIONS BETWEEN
COVID-19 AND SYSTEMIC
INFLAMMATORY RESPONSE INDUCED BY
LUNG INFLAMMATION
The exacerbated inflammatory response to acute lung injury is
more frequent in males and increases with age, being very low
in young individuals (15–19 years of age), whereas mortality
can reach up to 60% in individuals above 85 years of age (98).
Consequently, we suspect age-dependent responsiveness to lung
injury may contribute to the age-disparity of severe COVID-19,
with children under the age of 20 rarely developing severe disease
(25, 49). Other possibilities that may contribute to protection
of children from COVID-19 are frequent infection with mild
viruses and bacteria, vaccinations in their first decade of life,
and the lack of chronic underlying conditions observed in the
COVID-19 high risk groups. All of these likely contribute to high
levels of IgA in the upper respiratory tract, which may confer
cross-protection against SARS-CoV-2, coupled with high local
(or systemic) IFN-γ which could potentially reduce the COVID-
19 entry and multiplication success in younger individuals. This
protection may also be associated with “trained immunity” (99),
which is consistent with the prospect of using BCG vaccine as a
preventative treatment for SARS-CoV-2.
The regulation of the RAS system for COVID-19 has
been discussed from the cardiovascular viewpoint by Guo
et al. (100). A positive correlation between Angiotensin II
and lung SARS-CoV-2 viral load was described by Liu et al.
(101). There have been many attempts to neutralize the lung
inflammatory components using “imunoresolvents” for SIRS-
ALI with promising preclinical testing, such as for COVID-
19. Unfortunately, in an analysis between 22 preclinical and
clinical sepsis trials, these drugs failed to show benefit (102). It is
noteworthy that other randomized double blinded studies using
infliximab (anti-TNF-α), had no therapeutic benefit reducing
acute exacerbation of chronic obstructive pulmonary disease
(103). Statins represent another class of drugs with potential
to reduce inflammation and increase ACE2 expression (104).
Pro-resolving lipid mediators including resolvins, protectins, and
maresins have anti-inflammatory activity in lung inflammation
and might help in a treatment cocktail for COVID-19 (26). The
reasons why we think that a cocktail of treatments targeting
multiple aspects of this systemic presentation due to lung
injury is represented by the work of Cao et al. showing that
the antivirals Lopinavir-Ritonavir failed to reduce COVID-19
lethality, although it reduced the ICU time of recovered patients
by 5 days (105).
Antivirals coupled with bisphosphonates might be able
to impede progression of COVID-19 to severe and critical.
Antivirals combined with regulation of the causes for
coagulation and vascular dysfunction, thereby preventing
the lung from amplifying systemic inflammation due to
mechanical ventilation, comorbidity, or secondary infection
might also be of essence to reduce lethality and increase
recovery rate in COVID-19. Finally, as proposed by several
groups, antivirals coupled with drugs addressing CSS
can be also beneficial to prevent COVID-19 progression
(20, 106).
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